Related Experiment Video
Updated: Jan 14, 2026
Methodology for the Efficient Generation of Fluorescently Tagged Vaccinia Virus Proteins
Published on: January 17, 2014
Development and validation of an agent-based cost-effectiveness model of varicella vaccination strategies in
Brent Hodgkinson1, Paul Scuffham1
1Centre for Applied Health Economics, School of Medicine & Dentistry, Griffith University, Queensland, Australia.
Aims:
Varicella zoster virus (VZV) is highly infectious and initially presents as varicella (chickenpox, CP); following recovery VZV poses a lifetime risk of re-emergence as herpes zoster (shingles, HZ). At the time of this study, the Australian National Immunisation Program funded a single dose of VZV vaccine as MMRV (measles, mumps, rubella, varicella) at 18 months of age, and a HZ vaccine for persons aged 70 to 79 years. However, numerous studies have concluded that a two-dose VZV regimen during childhood may be more effective and that the optimal timing for HZ vaccination is uncertain. The aim of this paper was to describe the development and validation of an agent-based model designed to evaluate the cost-effectiveness of various varicella vaccination strategies in Australia.
Methods:
During calibration, model parameter values were similar to an earlier published model, with strong agreement between modelled and published CP seropositivity and HZ incidence. Modelling an unvaccinated population, the model displayed a steady state incidence of CP and HZ, with the associated hospitalisations, deaths, and costs in alignment with published values. In the vaccination scenario, the model predicted the marked reduction in CP incidence and characteristic initial increase in HZ reported in published studies.
Results:
During calibration, model parameter values were similar to an earlier published model, with strong agreement between modelled and published CP seropositivity and HZ incidence. Modelling an unvaccinated population, the model displayed a steady state incidence of CP and HZ, with the associated hospitalisations, deaths, and costs in alignment with published values. In the vaccination scenario, the model predicted the marked reduction in CP incidence and characteristic intial increase in HZ reported in published studies.
Conclusions:
This agent-based model can be used to provide cost-effectiveness estimates for various VZV vaccination strategies in an Australian context.
More Related Videos
08:04Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation
Published on: July 9, 2014
12:42Paramyxoviruses for Tumor-targeted Immunomodulation: Design and Evaluation Ex Vivo
Published on: January 7, 2019
Related Concept Videos
01:18Models of Health Promotion and Illness Prevention II
The agent-host-environment model states that disease results...
01:51Vaccinations
01:26Pharmacokinetic Models: Comparison and Selection Criterion
Physiological models take a detailed approach by considering specific molecular processes. They can predict drug distribution, metabolism, and elimination changes, providing a comprehensive understanding of how drugs interact with the body.
01:25Models of Health Promotion and Illness Prevention I
The health belief model (HBM) attempts to predict health-related behavior in specific belief patterns. According to the HBM, a person's...
01:25Statistical Methods for Analyzing Epidemiological Data
01:14Analysis Methods of Pharmacokinetic Data: Model and Model-Independent Approaches
The model approach uses mathematical models to describe changes in drug concentration over time. Pharmacokinetic models help characterize drug behavior in patients, predict drug concentration in the body fluids, calculate optimum dosage regimens, and evaluate the risk of toxicity. However, ensuring that the model fits the experimental data accurately...